Home
News
Create
Screeners
Insights
Fischer Medical Ventures
36.
60
+1.74
(+4.99%)
Market Cap
₹2,373.57 Cr
PE Ratio
57.30
Industry
Chemicals
Buy
Sell
Company Performance:
1D
+4.99%
1M
-10.54%
6M
-67.78%
1Y
-52.83%
5Y
-52.83%
View Company Insights
Latest news about Fischer Medical Ventures
Fischer Medical Ventures Opens Special Window for Physical Share Transfer Re-lodgement
6 days ago
Fischer Medical Ventures Limited has opened a special window from February 05, 2026 to February 04, 2027 for re-lodgement of physical share transfer requests that were previously rejected, returned, or not processed due to document deficiencies. The initiative follows SEBI Circular dated January 30, 2026, and was announced through newspaper advertisements in Financial Express and Vishalandra on March 12, 2026. Shareholders are advised to submit required documents to the company's Registrar and Share Transfer Agent during this 12-month window period.
Fischer Medical Ventures: Invests 75% In PT Fischer Pariko Medical Ventures Shares
Mar 04, 2026
Fischer Medical Ventures Promoter Pledges 30 Lakh Shares to HDFC Bank for Working Capital
Feb 06, 2026
Fischer Medical Ventures Reports Strong Q3FY26 Performance with Revenue Growth
Feb 02, 2026
Fischer Medical Ventures Approves Internal Group Reorganisation of Foreign Subsidiary Shares
Jan 21, 2026
More news about Fischer Medical Ventures
02
Jan 26
Fischer Medical Ventures Limited Updates Board Committee Composition in Regulatory Filing
Fischer Medical Ventures Limited disclosed updated board committee compositions on January 02, 2026, detailing the structure of Audit, Nomination & Remuneration, and Risk Management committees. The committees comprise independent directors, executive management, and senior officers, with Mr. Khairy Jamaluddin Abu Bakar chairing two committees and Ms. Svetlana Rao Raviwada leading the Risk Management Committee.
28
Oct 25
Fischer Medical Ventures Reports Robust Q2 Growth with 46-Fold Increase in Net Profit
Fischer Medical Ventures, a medical technology company, reported a significant financial performance boost in Q2. Net profit surged to 139.00 million rupees from 3.00 million rupees year-over-year, a 46-fold increase. Revenue more than doubled to 863.00 million rupees from 397.00 million rupees. The company also announced board changes, appointing Mr. Chan Sing En as Additional Non-Executive Independent Director and recommending Tan Sri Dato' Dr. Syed Jalaludin as Independent Director, both for five-year terms subject to shareholder approval.
Fischer Medical Ventures
36.
60
+
1.
74
(+
4.
99
%)
1 Year Returns:
-52.83%
Industry Peers
Tata Chemicals
650.45
(-
0.
86
%)
Deepak Fertilisers & Petrochemicals
943.40
(+
3.
73
%)
Gujarat Narmada Valley Fert & Chem
420.60
(+
1.
99
%)
Chemplast Sanmar
276.00
(+
6.
45
%)
GHCL
451.15
(+
0.
20
%)
TANFAC Industries
1,680.90
(+
1.
41
%)
Gujarat Alkalies & Chemicals
432.10
(+
4.
33
%)
Fischer Medical Ventures
36.60
(+
4.
99
%)
Citurgia Biochemicals
167.40
(+
4.
99
%)
Thirumalai Chemicals
183.05
(+
11.
38
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO